Abstract: A urea production plant including a synthesis and recovery section has a first evaporation section connected with the synthesis and recovery section and a first condensation section. A granulation section is connected to the first evaporation section. A scrubbing section is connected to the granulation section. A second evaporation section is connected to the scrubbing section. The second evaporation section is connected to the granulation section. A second condensation section is connected to the second evaporation section. A quenching section includes a liquid inlet for the distribution of a quenching liquid is located and connected between the granulation section and the scrubbing section and the quenching section is connected to a quenching liquid providing section and the second condensation section.

Abstract: A plant extract, derived from a Salvia spp, may include one of at least one tanshinone compound, or at least one tanshinone compounds including a CYP11B1 inhibitory amount of at least one of tanshinone I and dihydrotanshinone. The plant extract may be used for use in the treatment of a wound or Cushing's syndrome.

Abstract: Systems and methods for receiving touch-based input from an operator of an imaging device are disclosed herein. In one embodiment, an ultrasound imaging device is configured to receive tactile input from an operator. The imaging device presents an ultrasound image to the operator and the operator can perform one or more touch inputs on the image. Based on the received input, the imaging device can update the display of the image.

Abstract: The present invention relates to a transdermal therapeutical system for the administration of physostigmine to the skin via a cover layer which is impermeable to active substances, a pressure-sensitive adhesive reservoir layer, and optionally a removable protective layer, said reservoir layer consisting of 10-90% polymeric material selected from the groups consisting of block copolymers on the basis of styrene and 1,3-dienes, polyisobutylenes, polymers on the basis of acrylates and/or methacrylates and esters of hydrogenated colophonium, 0-30%-wt softeners on the basis of hydrocarbons and/or esters, and 0.1-20%-wt physostigmine.